New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
09:06 EDTINSVInSite Vision momentum turning positive, says Roth Capital
Roth Capital believes that recent events, including a patent that InSite received for BromSite and the company's collaboration with Senju Pharmaceutical in Japan, are positive and set the stage for larger business development deals. The firm keeps a Buy rating on the stock for speculative investors.
News For INSV From The Last 14 Days
Check below for free stories on INSV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2014
08:35 EDTINSVInSite Vision issued U.S. patent covering Bromfenac formulations in DuraSite
InSite Vision Incorporated announced that the United States Patent and Trademark Office has issued a U.S. Patent No. 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. The allowed patent contains both composition and method of treatment claims that will broadly cover all of InSite’s bromfenac product candidates, including BromSite for the treatment of inflammation and prevention of pain post cataract surgery. Additional bromfenac-containing products in InSite’s pipeline covered under this patent include: ISV-101 for the treatment of dry eye disease, back-of-the eye BromSite indications, such as the prevention of cystoid macular edema, as well as the combination of bromfenac and dexamethasone containing products such as BromDex. Due to USPTO delays, the patent term was extended by 155 days to provide protection for bromfenac formulations in DuraSite to August 2029.
July 8, 2014
08:35 EDTINSVInSite Vision plans to submit NDA for DexaSite for treatment of blepharitis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use